Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.41 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2822925 | 0.86 | ALDH1A1 (0.47) | ALDH1A1SMN1; SMN2HTTCYP2C9KMT2A | |
| SCHEMBL693478 | 0.84 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2HTTKMT2AMEN1 | |
| SCHEMBL693154 | 0.84 | USP2 (0.54) | ALDH1A1SMN1; SMN2CYP2C9KMT2AMEN1 | |
| SCHEMBL13113196 | 0.82 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2HTTKMT2ALMNA | |
| SCHEMBL695019 | 0.82 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2CYP2C9KMT2AMEN1 | |
| SCHEMBL693425 | 0.82 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2HTTCYP2C9KMT2A | |
| SCHEMBL693597 | 0.81 | LMNA (0.49) | ALDH1A1SMN1; SMN2HTTCYP2C9LMNA | |
| SCHEMBL3111754 | 0.81 | MAPT (0.52) | ALDH1A1SMN1; SMN2HTTKMT2AMEN1 | |
| SCHEMBL693652 | 0.81 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2HTTCYP2C9KMT2A | |
| SCHEMBL691478 | 0.81 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2HTTCYP2C9KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2421829-B1 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS INC (US) | 2015-09-30 | — | — | EP | disclosed |
| EP-2727908-A2 | 2,5-disubstituted arylsulfonamide CCR3 antagonists | Axikin Pharmaceuticals, Inc. (US) | 2014-05-07 | — | — | EP | disclosed |
| EP-2727908-A2 | 2,5-disubstituted arylsulfonamide CCR3 antagonists | Axikin Pharmaceuticals, Inc. (US) | 2014-05-07 | — | — | EP | disclosed |
| US-8669247-B2 | 2,5-disubstituted arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS, INC. (US) | 2014-03-11 | — | — | US | disclosed |
| US-8669247-B2 | 2,5-disubstituted arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS, INC. (US) | 2014-03-11 | — | — | US | disclosed |
| US-8669247-B2 | 2,5-disubstituted arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS, INC. (US) | 2014-03-11 | — | — | US | disclosed |
| US-20130225565-A1 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225565-A1 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225565-A1 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-8399456-B2 | 2,5-disubstituted arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399456-B2 | 2,5-disubstituted arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399456-B2 | 2,5-disubstituted arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| EP-2421829-A2 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | Axikin Pharmaceuticals, Inc. (US) | 2012-02-29 | — | — | EP | disclosed |
| US-20100273782-A1 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2010-10-28 | — | — | US | disclosed |
| US-20100273782-A1 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2010-10-28 | — | — | US | disclosed |
| US-20100273782-A1 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2010-10-28 | — | — | US | disclosed |
| WO-2010123956-A2 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010123956-A2 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225565-A1 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | CCR3, CCR1, CCR4 | ALDH1A1 1818/4885SMN1; SMN2 837/4885HTT 3242/4885 |
| US-20100273782-A1 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | CCR3, CCR1, CCR4 | ALDH1A1 1818/4885SMN1; SMN2 837/4885HTT 3242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.